Shares of Sage Therapeutics stock opened at $7.14 on Wednesday. The company has a market cap of $438.97 million, a P/E ratio of -1.28 and a beta of 0.94. The firm’s 50 day moving average price ...

Shares of SAGE stock opened at $7.14 on Wednesday. The company has a market capitalization of $438.97 million, a P/E ratio of -1.28 and a beta of 0.94. Sage Therapeutics has a fifty-two week low ...

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The company’s shares closed yesterday at $7.16. Leverage the ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $0.55 per share a year ago.

Sage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.45. The company had reported a loss of 55 ...

Throughout the last three months, 7 analysts have evaluated Sage Therapeutics (NASDAQ:SAGE), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

Sage Therapeutics, Inc. NASDAQ: SAGE) is officially exploring "strategic alternatives" to make shareholders happy. The process includes anything from a possible business combination to a full-on sale.